A Phase Ia/Ib Study Assessing Single and Multiple Doses of CDI-31244: A Non-Nucleoside Inhibitor in Healthy and Hepatitis C Virus-Infected Subjects

Trial Profile

A Phase Ia/Ib Study Assessing Single and Multiple Doses of CDI-31244: A Non-Nucleoside Inhibitor in Healthy and Hepatitis C Virus-Infected Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs CC 31244 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man
  • Sponsors Cocrystal Pharma Inc
  • Most Recent Events

    • 15 Aug 2017 Results published in a Cocrystal Pharma media release.
    • 18 Jul 2017 Status changed from recruiting to completed.
    • 03 Apr 2017 According to a Cocrystal Pharma Inc media release, interim results from the study were presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top